Shatavari,
does it really help with Improvement of menopausal symptoms and female sexual function?
research showsStandalone standardized shatavari extract has real RCTs in 70 and 80 women for menopausal symptoms and in 135 women for sexual function, so this is not a case for an indeterminate rating. However, all lasted eight weeks, emphasized multiple self-reported endpoints, and were linked to commercial standardized ingredients including Ixoreal. Without independent long-term replication, the grade is C.
ads claimAdvertisements use phrases such as 'female hormone balance,' 'estrogen booster,' 'solves all menopausal symptoms,' and 'improves libido, lubrication, and orgasm.' The actual data are short-term symptom-scale results for specific standardized extracts and did not test equivalence to hormone therapy or long-term effects.
Useful facts when choosing a product
- Trials used about 100-300 mg/day of standardized root extract, varying by product.
- Main endpoints were patient-reported scales such as MRS, MENQOL, hot-flash scores, and FSFI.
- Some studies compared both shatavari alone and shatavari plus ashwagandha, so combination-arm results cannot be assigned to shatavari alone.
- Adverse events were generally mild in 8-16-week trials, but long-term safety and safety in hormone-sensitive conditions have not been adequately tested.
What the research actually shows
Gudise 2024 reported improvement in hot flashes, night sweats, insomnia, anxiety, vaginal dryness, libido, and Utian quality of life in an eight-week double-blind trial of 70 menopausal women. Mahajan 2025 reported improved MRS, PSS, and hot flashes after 300 mg/day for eight weeks in 80 perimenopausal women. Ademola 2026 assigned 135 women across three groups and found that shatavari alone improved total FSFI and satisfaction versus placebo after eight weeks, but the duration was short and Ixoreal supplied the product.
Why this is classified as C (48)
RCTs of 70, 80, and 135 participants exist, so ? is not appropriate. Eight-week duration, multiple self-reported endpoints, concentration on commercial standardized ingredients including Ixoreal, and no independent long-term replication result in C with 48 points.
Counterpoint. Menopause and sexual-function signals have recurred across different studies since 2024. The evidence assessment could change if a preregistered independent long-term multicenter trial reproduces the effect size.
Rejudgment record. Reassessment (cross-check reflected) — RCTs of 70 and 80 participants for menopause and 135 for sexual function exist, but all lasted eight weeks, used multiple self-reported endpoints, centered on commercial ingredients including Ixoreal, and lack independent long-term replication, supporting C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement of menopausal symptoms | C | Several recent small short RCTs are positive, but commercial-ingredient links and limited independent replication remain. |
| Improvement of female sexual function | C | A 135-person eight-week RCT was positive for total FSFI and satisfaction, but it is a short result from one research network. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gudise VS et al. 2024 | Multicenter double-blind randomized placebo-controlled trial | 70 | Used the commercial standardized product Aspurūs; details unclear | Hot flashes, night sweats, sleep, libido, and Utian QoL | Reported improvement in multiple symptoms and quality of life after eight weeks, but the trial was small and short. | Key |
| Mahajan S et al. 2025 | Randomized double-blind placebo-controlled trial | 73 | Specific standardized extract; no funding or conflicts reported | MRS, MENQOL, PSS, hot flashes, and hormones | Reported improved MRS, PSS, and hot flashes after 300 mg/day for eight weeks. | Key |
| Ademola J et al. 2026 | Three-arm randomized double-blind placebo-controlled trial | 135 | No specific funding reported; products supplied by Ixoreal Biomed | FSFI, FSDS, intercourse frequency, mood, and sleep | Shatavari alone improved total FSFI, satisfaction, and FSDS versus placebo after eight weeks. | Key |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-11).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Shatavari (Asparagus racemosus) x improvement of menopausal symptoms and female sexual function — Evidence Grade C·48. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/womens/shatavari-menopause-sexual-function/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.